secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0000950170-23-003808
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio discontinues sickle cell gene therapy nula-cel, cuts workforce 50%, explores strategic alternatives
--------------------------------------------------------------------------------

- Discontinues development of nula-cel for sickle cell disease; exploring external continuation.
- Reduces workforce by approximately 50%; expects severance costs of ~$4.9M in Q2 2023.
- Chief Business Officer and Chief Scientific Officer to depart in Q2 2023.
- Preliminary unaudited cash, equivalents, and marketable securities of ~$283.5M as of Dec 31, 2022.
- Will continue early-stage non-genotoxic conditioning program; board approved restructuring.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023003808/0000950170-23-003808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023003808/grph-20230216.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-003808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer